002432 九安医疗
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,350,913-40.82%3,231,12526,315,3612,397,0982,008,360
减:营业总成本906,872-28.09%2,186,3117,434,7301,447,6841,572,994
    其中:营业成本402,299-47.85%1,176,5725,367,195875,549877,505
               财务费用5,835-103.26%(199,522)(209,149)2,60218,784
               资产减值损失(8,913)-97.31%(309,867)(321,559)(9,274)(177,698)
公允价值变动收益67,692-60.79%309,288(326,401)30,489(335,946)
投资收益339,03056.26%560,73893,48345,583317,541
    其中:对联营企业和合营企业的投资收益----(1,679)(1,266)(1,380)(332)
营业利润842,757-22.95%1,613,49118,311,8691,002,549238,588
利润总额842,184-23.09%1,580,34418,257,857999,632239,753
减:所得税费用141,1630.77%231,1121,773,76365,2292,925
净利润701,021-26.59%1,349,23216,484,094934,403236,828
减:非控股权益99,261-41.31%97,624453,92525,761(5,501)
股东净利润601,760-23.42%1,251,60816,030,169908,642242,329

市场价值指针
每股收益 (元) *1.379-17.36%2.81535.1381.9990.560
每股派息 (元) *----0.3002.5000.7000.060
每股净资产 (元) *----39.38140.3575.9674.355
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容